Does CAPMATINIB Cause Malignant neoplasm progression? 178 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 178 reports of Malignant neoplasm progression have been filed in association with CAPMATINIB (TABRECTA). This represents 7.7% of all adverse event reports for CAPMATINIB.
178
Reports of Malignant neoplasm progression with CAPMATINIB
7.7%
of all CAPMATINIB reports
79
Deaths
42
Hospitalizations
How Dangerous Is Malignant neoplasm progression From CAPMATINIB?
Of the 178 reports, 79 (44.4%) resulted in death, 42 (23.6%) required hospitalization, and 11 (6.2%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for CAPMATINIB. However, 178 reports have been filed with the FAERS database.
What Other Side Effects Does CAPMATINIB Cause?
Death (411)
Peripheral swelling (283)
Fatigue (257)
Oedema peripheral (247)
Nausea (240)
Dyspnoea (141)
Oedema (130)
Asthenia (113)
Non-small cell lung cancer (96)
Decreased appetite (95)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which CAPMATINIB Alternatives Have Lower Malignant neoplasm progression Risk?
CAPMATINIB vs CAPREOMYCIN
CAPMATINIB vs CAPSAICIN
CAPMATINIB vs CAPTOPRIL
CAPMATINIB vs CARBAMAZEPINE
CAPMATINIB vs CARBETOCIN